Loading…
Acute Gouty Arthritis During Favipiravir Treatment for Coronavirus Disease 2019
A 42-year-old man exhibiting hypoxia was diagnosed with coronavirus disease 2019. He had medical histories of type 2 diabetes, hyperlipidemia, hyperuricemia, and gout attack. He received favipiravir for compassionate use for 14 days. Subsequently, he showed increased uric acid levels and developed a...
Saved in:
| Published in: | Internal Medicine 2020/09/15, Vol.59(18), pp.2327-2329 |
|---|---|
| Main Authors: | , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c667t-2e8b3254d56b8b18d412140fdcc6315f860e58c06cf6943581623ec2629a76673 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c667t-2e8b3254d56b8b18d412140fdcc6315f860e58c06cf6943581623ec2629a76673 |
| container_end_page | 2329 |
| container_issue | 18 |
| container_start_page | 2327 |
| container_title | Internal Medicine |
| container_volume | 59 |
| creator | Hase, Ryota Kurata, Rika Ishida, Keiko Kurita, Takashi Muranaka, Emiri Mito, Haruki |
| description | A 42-year-old man exhibiting hypoxia was diagnosed with coronavirus disease 2019. He had medical histories of type 2 diabetes, hyperlipidemia, hyperuricemia, and gout attack. He received favipiravir for compassionate use for 14 days. Subsequently, he showed increased uric acid levels and developed acute gouty arthritis. Favipiravir may induce not only hyperuricemia but also acute gouty arthritis. It should therefore be used with caution in patients with a history of gout and those with hyperuricemia, especially when used at a higher dose and for a longer duration than is typical. |
| doi_str_mv | 10.2169/internalmedicine.5377-20 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7578611</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2447950282</sourcerecordid><originalsourceid>FETCH-LOGICAL-c667t-2e8b3254d56b8b18d412140fdcc6315f860e58c06cf6943581623ec2629a76673</originalsourceid><addsrcrecordid>eNptkVtrGzEQhUVoSdy0fyEI8ryJNFrdXgLGzaUQ8Ev6LGRZa8vYK1fSBvLvo8WOSUtfjkDzzZlhDkKYkhugQt-GvvjU2-3OL4MLvb_hTMoGyBmaUNbqRgLjX9CEaKoaqHKBvuW8IYQpqeEcXTCQILUWEzSfuqF4_BiH8oanqaxTKCHjn0MK_Qo_2NewD6lqwi_J27LzfcFdTHgWU-zH_6HCIXubPQZC9Xf0tbPb7H8c30v0--H-ZfbUPM8ff82mz40TQpYGvFow4O2Si4VaULVsKdCWdEvnBKO8U4J4rhwRrhO6ZVxRAcw7EKCtrA7sEt0dfPfDol7B1b2S3Zp9Cjub3ky0wfxd6cParOKrkVwqQWk1uD4apPhn8LmYTRzGm2YDbSs1J6CgUupAuRRzTr47TaDEjFGYf6MwYxQGSG29-rzhqfHj9hWYH4BNLnblT4BNJbit_4-zNlSNehxxIt3aJuN79g53oae2</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2447950282</pqid></control><display><type>article</type><title>Acute Gouty Arthritis During Favipiravir Treatment for Coronavirus Disease 2019</title><source>PubMed Central</source><creator>Hase, Ryota ; Kurata, Rika ; Ishida, Keiko ; Kurita, Takashi ; Muranaka, Emiri ; Mito, Haruki</creator><creatorcontrib>Hase, Ryota ; Kurata, Rika ; Ishida, Keiko ; Kurita, Takashi ; Muranaka, Emiri ; Mito, Haruki</creatorcontrib><description>A 42-year-old man exhibiting hypoxia was diagnosed with coronavirus disease 2019. He had medical histories of type 2 diabetes, hyperlipidemia, hyperuricemia, and gout attack. He received favipiravir for compassionate use for 14 days. Subsequently, he showed increased uric acid levels and developed acute gouty arthritis. Favipiravir may induce not only hyperuricemia but also acute gouty arthritis. It should therefore be used with caution in patients with a history of gout and those with hyperuricemia, especially when used at a higher dose and for a longer duration than is typical.</description><identifier>ISSN: 0918-2918</identifier><identifier>EISSN: 1349-7235</identifier><identifier>DOI: 10.2169/internalmedicine.5377-20</identifier><identifier>PMID: 32727996</identifier><language>eng</language><publisher>Japan: The Japanese Society of Internal Medicine</publisher><subject>acute gouty arthritis ; Adult ; Amides - adverse effects ; Amides - therapeutic use ; Antiviral Agents - adverse effects ; Antiviral Agents - therapeutic use ; Arthritis ; Arthritis, Gouty - chemically induced ; Betacoronavirus ; Case Report ; coronavirus disease 2019 (COVID-19) ; Coronavirus Infections - complications ; Coronavirus Infections - drug therapy ; Coronaviruses ; COVID-19 ; Diabetes mellitus (non-insulin dependent) ; favipiravir ; Gout ; Humans ; Hyperlipidemia ; Hyperuricemia ; Hyperuricemia - complications ; Hypoxia ; Internal medicine ; Lung - diagnostic imaging ; Lung - pathology ; Male ; Pandemics ; Pneumonia, Viral - complications ; Pneumonia, Viral - drug therapy ; Pyrazines - adverse effects ; Pyrazines - therapeutic use ; Rheumatism ; SARS-CoV-2 ; severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) ; Uric acid ; Uric Acid - urine</subject><ispartof>Internal Medicine, 2020/09/15, Vol.59(18), pp.2327-2329</ispartof><rights>2020 by The Japanese Society of Internal Medicine</rights><rights>Copyright Japan Science and Technology Agency 2020</rights><rights>Copyright © 2020 by The Japanese Society of Internal Medicine</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c667t-2e8b3254d56b8b18d412140fdcc6315f860e58c06cf6943581623ec2629a76673</citedby><cites>FETCH-LOGICAL-c667t-2e8b3254d56b8b18d412140fdcc6315f860e58c06cf6943581623ec2629a76673</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7578611/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7578611/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27903,27904,53770,53772</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32727996$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hase, Ryota</creatorcontrib><creatorcontrib>Kurata, Rika</creatorcontrib><creatorcontrib>Ishida, Keiko</creatorcontrib><creatorcontrib>Kurita, Takashi</creatorcontrib><creatorcontrib>Muranaka, Emiri</creatorcontrib><creatorcontrib>Mito, Haruki</creatorcontrib><title>Acute Gouty Arthritis During Favipiravir Treatment for Coronavirus Disease 2019</title><title>Internal Medicine</title><addtitle>Intern. Med.</addtitle><description>A 42-year-old man exhibiting hypoxia was diagnosed with coronavirus disease 2019. He had medical histories of type 2 diabetes, hyperlipidemia, hyperuricemia, and gout attack. He received favipiravir for compassionate use for 14 days. Subsequently, he showed increased uric acid levels and developed acute gouty arthritis. Favipiravir may induce not only hyperuricemia but also acute gouty arthritis. It should therefore be used with caution in patients with a history of gout and those with hyperuricemia, especially when used at a higher dose and for a longer duration than is typical.</description><subject>acute gouty arthritis</subject><subject>Adult</subject><subject>Amides - adverse effects</subject><subject>Amides - therapeutic use</subject><subject>Antiviral Agents - adverse effects</subject><subject>Antiviral Agents - therapeutic use</subject><subject>Arthritis</subject><subject>Arthritis, Gouty - chemically induced</subject><subject>Betacoronavirus</subject><subject>Case Report</subject><subject>coronavirus disease 2019 (COVID-19)</subject><subject>Coronavirus Infections - complications</subject><subject>Coronavirus Infections - drug therapy</subject><subject>Coronaviruses</subject><subject>COVID-19</subject><subject>Diabetes mellitus (non-insulin dependent)</subject><subject>favipiravir</subject><subject>Gout</subject><subject>Humans</subject><subject>Hyperlipidemia</subject><subject>Hyperuricemia</subject><subject>Hyperuricemia - complications</subject><subject>Hypoxia</subject><subject>Internal medicine</subject><subject>Lung - diagnostic imaging</subject><subject>Lung - pathology</subject><subject>Male</subject><subject>Pandemics</subject><subject>Pneumonia, Viral - complications</subject><subject>Pneumonia, Viral - drug therapy</subject><subject>Pyrazines - adverse effects</subject><subject>Pyrazines - therapeutic use</subject><subject>Rheumatism</subject><subject>SARS-CoV-2</subject><subject>severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2)</subject><subject>Uric acid</subject><subject>Uric Acid - urine</subject><issn>0918-2918</issn><issn>1349-7235</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNptkVtrGzEQhUVoSdy0fyEI8ryJNFrdXgLGzaUQ8Ev6LGRZa8vYK1fSBvLvo8WOSUtfjkDzzZlhDkKYkhugQt-GvvjU2-3OL4MLvb_hTMoGyBmaUNbqRgLjX9CEaKoaqHKBvuW8IYQpqeEcXTCQILUWEzSfuqF4_BiH8oanqaxTKCHjn0MK_Qo_2NewD6lqwi_J27LzfcFdTHgWU-zH_6HCIXubPQZC9Xf0tbPb7H8c30v0--H-ZfbUPM8ff82mz40TQpYGvFow4O2Si4VaULVsKdCWdEvnBKO8U4J4rhwRrhO6ZVxRAcw7EKCtrA7sEt0dfPfDol7B1b2S3Zp9Cjub3ky0wfxd6cParOKrkVwqQWk1uD4apPhn8LmYTRzGm2YDbSs1J6CgUupAuRRzTr47TaDEjFGYf6MwYxQGSG29-rzhqfHj9hWYH4BNLnblT4BNJbit_4-zNlSNehxxIt3aJuN79g53oae2</recordid><startdate>20200915</startdate><enddate>20200915</enddate><creator>Hase, Ryota</creator><creator>Kurata, Rika</creator><creator>Ishida, Keiko</creator><creator>Kurita, Takashi</creator><creator>Muranaka, Emiri</creator><creator>Mito, Haruki</creator><general>The Japanese Society of Internal Medicine</general><general>Japan Science and Technology Agency</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TK</scope><scope>7U9</scope><scope>H94</scope><scope>5PM</scope></search><sort><creationdate>20200915</creationdate><title>Acute Gouty Arthritis During Favipiravir Treatment for Coronavirus Disease 2019</title><author>Hase, Ryota ; Kurata, Rika ; Ishida, Keiko ; Kurita, Takashi ; Muranaka, Emiri ; Mito, Haruki</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c667t-2e8b3254d56b8b18d412140fdcc6315f860e58c06cf6943581623ec2629a76673</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>acute gouty arthritis</topic><topic>Adult</topic><topic>Amides - adverse effects</topic><topic>Amides - therapeutic use</topic><topic>Antiviral Agents - adverse effects</topic><topic>Antiviral Agents - therapeutic use</topic><topic>Arthritis</topic><topic>Arthritis, Gouty - chemically induced</topic><topic>Betacoronavirus</topic><topic>Case Report</topic><topic>coronavirus disease 2019 (COVID-19)</topic><topic>Coronavirus Infections - complications</topic><topic>Coronavirus Infections - drug therapy</topic><topic>Coronaviruses</topic><topic>COVID-19</topic><topic>Diabetes mellitus (non-insulin dependent)</topic><topic>favipiravir</topic><topic>Gout</topic><topic>Humans</topic><topic>Hyperlipidemia</topic><topic>Hyperuricemia</topic><topic>Hyperuricemia - complications</topic><topic>Hypoxia</topic><topic>Internal medicine</topic><topic>Lung - diagnostic imaging</topic><topic>Lung - pathology</topic><topic>Male</topic><topic>Pandemics</topic><topic>Pneumonia, Viral - complications</topic><topic>Pneumonia, Viral - drug therapy</topic><topic>Pyrazines - adverse effects</topic><topic>Pyrazines - therapeutic use</topic><topic>Rheumatism</topic><topic>SARS-CoV-2</topic><topic>severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2)</topic><topic>Uric acid</topic><topic>Uric Acid - urine</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hase, Ryota</creatorcontrib><creatorcontrib>Kurata, Rika</creatorcontrib><creatorcontrib>Ishida, Keiko</creatorcontrib><creatorcontrib>Kurita, Takashi</creatorcontrib><creatorcontrib>Muranaka, Emiri</creatorcontrib><creatorcontrib>Mito, Haruki</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Internal Medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hase, Ryota</au><au>Kurata, Rika</au><au>Ishida, Keiko</au><au>Kurita, Takashi</au><au>Muranaka, Emiri</au><au>Mito, Haruki</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Acute Gouty Arthritis During Favipiravir Treatment for Coronavirus Disease 2019</atitle><jtitle>Internal Medicine</jtitle><addtitle>Intern. Med.</addtitle><date>2020-09-15</date><risdate>2020</risdate><volume>59</volume><issue>18</issue><spage>2327</spage><epage>2329</epage><pages>2327-2329</pages><issn>0918-2918</issn><eissn>1349-7235</eissn><abstract>A 42-year-old man exhibiting hypoxia was diagnosed with coronavirus disease 2019. He had medical histories of type 2 diabetes, hyperlipidemia, hyperuricemia, and gout attack. He received favipiravir for compassionate use for 14 days. Subsequently, he showed increased uric acid levels and developed acute gouty arthritis. Favipiravir may induce not only hyperuricemia but also acute gouty arthritis. It should therefore be used with caution in patients with a history of gout and those with hyperuricemia, especially when used at a higher dose and for a longer duration than is typical.</abstract><cop>Japan</cop><pub>The Japanese Society of Internal Medicine</pub><pmid>32727996</pmid><doi>10.2169/internalmedicine.5377-20</doi><tpages>3</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0918-2918 |
| ispartof | Internal Medicine, 2020/09/15, Vol.59(18), pp.2327-2329 |
| issn | 0918-2918 1349-7235 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7578611 |
| source | PubMed Central |
| subjects | acute gouty arthritis Adult Amides - adverse effects Amides - therapeutic use Antiviral Agents - adverse effects Antiviral Agents - therapeutic use Arthritis Arthritis, Gouty - chemically induced Betacoronavirus Case Report coronavirus disease 2019 (COVID-19) Coronavirus Infections - complications Coronavirus Infections - drug therapy Coronaviruses COVID-19 Diabetes mellitus (non-insulin dependent) favipiravir Gout Humans Hyperlipidemia Hyperuricemia Hyperuricemia - complications Hypoxia Internal medicine Lung - diagnostic imaging Lung - pathology Male Pandemics Pneumonia, Viral - complications Pneumonia, Viral - drug therapy Pyrazines - adverse effects Pyrazines - therapeutic use Rheumatism SARS-CoV-2 severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) Uric acid Uric Acid - urine |
| title | Acute Gouty Arthritis During Favipiravir Treatment for Coronavirus Disease 2019 |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-21T13%3A54%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Acute%20Gouty%20Arthritis%20During%20Favipiravir%20Treatment%20for%20Coronavirus%20Disease%202019&rft.jtitle=Internal%20Medicine&rft.au=Hase,%20Ryota&rft.date=2020-09-15&rft.volume=59&rft.issue=18&rft.spage=2327&rft.epage=2329&rft.pages=2327-2329&rft.issn=0918-2918&rft.eissn=1349-7235&rft_id=info:doi/10.2169/internalmedicine.5377-20&rft_dat=%3Cproquest_pubme%3E2447950282%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c667t-2e8b3254d56b8b18d412140fdcc6315f860e58c06cf6943581623ec2629a76673%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2447950282&rft_id=info:pmid/32727996&rfr_iscdi=true |